DDInter1271 DDInter1376
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nebivolol {u} (Compound) treats {v} (Disease) hypertension
Nebivolol {u} (Compound) binds {v} (Gene) ADRB2
Nebivolol {u} (Compound) causes {v} (Side Effect) Headache
Nebivolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Nebivolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Nebivolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Physostigmine
Nebivolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Nebivolol {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Nebivolol {u} may lead to a major life threatening interaction when taken with {v} Dyphylline
Nebivolol (Compound) treats hypertension (Disease)
Nebivolol (Compound) binds ADRB2 (Gene)
Nebivolol (Compound) causes Headache (Side Effect)
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Nebivolol may lead to a major life threatening interaction when taken with Fingolimod
Nebivolol may lead to a major life threatening interaction when taken with Dyphylline